Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Drugs aid weight loss among type 2 diabetes patients

18.02.2005


Three commonly used drugs -- Prozac, Xenical and Meridia -- may help type 2 diabetes patients lose small amounts of weight, although long-term benefits are not clear, a new review of 22 studies suggests.



Prozac and Sarafem, known generically as fluoxetine, are most commonly prescribed as antidepressants. Xenical, the brand name for orlistat, blocks fat digestion in the intestines. Meridia, known generically as subtramine, is an appetite suppressant that works in the brain.

According to the systematic evidence review by Dr. Susan Norris of the U.S. Centers for Disease Control and Prevention and colleagues, patients taking fluoxetine had lost an average of 11 pounds (5.1 kilograms) 24 to 26 weeks after starting the therapy. Patients taking orlistat had lost an average of four and a half pounds (two kilograms) 12 to 57 weeks later, and those taking sibutramine had lost an average of 11 pounds 12 to 52 weeks later. “The magnitude of weight loss is modest, however, and the long-term health benefits remain unclear,” the review concludes.


Side effects of the therapies included oily bowel movements for those taking orlistat; sweating, tremors and drowsiness among fluoxetine users; and heart palpitations in some sibutramine patients.

Although the researchers acknowledge that long-term weight loss is “of paramount importance,” they say their review could help determine how weight loss drugs should fit into the overall picture of type 2 diabetes care. “For example, if weight loss can be demonstrated with drugs in the short term, pharmacotherapy may be combined with behavioral interventions for long-term weight control,” Norris says.

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Although a variety of other weight loss drugs exist, only 22 randomized controlled studies of fluoxetine, orlistat and sibutramine met the high standards set by the researchers for inclusion in the review.

Of the 22 studies reviewed, the drugs’ manufacturers paid for 18 of them and did not provide the reviewers with unpublished studies the companies had done on each of the included drugs, Norris says. Norris says there is only a small amount of data on other weight loss drugs and people with type 2 diabetes. For instance, the researchers did not find any good studies examining the effects of popular weight loss drugs like ephedra in diabetic patients.

Obesity has been closely linked with type 2 diabetes. In a 2000 study, 80 to 90 percent of people with type 2 diabetes are overweight. Obesity may also worsen problems associated with diabetes, including high blood sugar, high cholesterol and high blood pressure, say Norris and colleagues. Norris says people with diabetes who are also overweight may have a harder time losing weight than non-diabetics.

Insulin therapy itself might cause weight gain, Norris says. Keeping track of a complex series of treatments for diabetes, high cholesterol and high blood pressure “all complicate behavioral change aimed at weight reduction.”

Recommendations by the American Diabetes Association in 2002 say that weight loss drugs may be useful in treating obesity among type 2 diabetes patients, but also note that “these drugs work best in conjunction with lifestyle strategies” such as low fat diets and increased exercise.

Norris and colleagues say more research is needed to find out whether weight loss drugs work better when combined with diet and exercise changes.

“In general populations, drugs have been combined with various lifestyle interventions, but most [drug] trials include relatively weak lifestyle programs, perhaps in part to better reveal the medication effects,” Norris says.

1. Norris et al. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus (Review).The Cochrane Database of Systematic Reviews 2005, Issue 1

Susan Norris | EurekAlert!
Further information:
http://www.hbns.org

More articles from Studies and Analyses:

nachricht Antarctic Ice Sheet mass loss has increased
14.06.2018 | Technische Universität Dresden

nachricht WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Temperature-controlled fiber-optic light source with liquid core

In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.

Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...

Im Focus: Overdosing on Calcium

Nano crystals impact stem cell fate during bone formation

Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Creating a new composite fuel for new-generation fast reactors

20.06.2018 | Materials Sciences

Game-changing finding pushes 3D-printing to the molecular limit

20.06.2018 | Materials Sciences

Could this material enable autonomous vehicles to come to market sooner?

20.06.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>